Dongwu Securities released a research report on April 26 stating that it gave Nanwei Medicine (688029.SH) a purchase rating. The main reasons for the rating include: 1) steady growth in various domestic businesses in 2023; 2) the gradual opening up of overseas markets and the commencement of production base construction in Thailand; 3) significant cost reduction and efficiency increases, and net interest rates continue to rise. (Mainichi Keizai Shimbun)
东吴证券4月26日发布研报称，给予南微医学（688029.SH）买入评级。评级理由主要包括：1）2023年国内各项业务稳健增长；2）海外市场逐步打开，启动泰国生产基地建设；3）降本增效显著，净利率持续提升。（每日经济新闻）
Dongwu Securities released a research report on April 26 stating that it gave Nanwei Medicine (688029.SH) a purchase rating. The main reasons for the rating include: 1) steady growth in various domestic businesses in 2023; 2) the gradual opening up of ove
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.